Mirum Pharmaceuticals is scheduled to report results from its phase 3 clinical study of LIVMARLI on Monday, according to multiple outlets.
The reporting concerns LIVMARLI (maralixibat), an investigational or studied therapy in the company’s broader clinical program. The announcements set expectations for how the trial performs, including key efficacy and safety outcomes, though specific figures and conclusions are not provided in the reports shared here.
While both outlets focus on the same upcoming disclosure, their framing differs: one piece emphasizes that the results will be released Monday, while the other highlights that the company will share phase 3 study results. Neither source, based on the information provided, describes the trial’s findings in detail, the status of regulatory review, or the implications for future timelines. Market and stakeholder attention is directed toward the forthcoming publication and any updates it may bring for the program.
